Open AccessDiscovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer
Author(s) -
Jun Liang,
Robert A. Blake,
Jae H. Chang,
Lori S. Friedman,
Simon Goodacre,
Steven J. Hartman,
Ellen Ingalla,
James R. Kiefer,
Tracy Kleinheinz,
Sharada S. Labadie,
Jun Li,
Kwong Wah Lai,
Jiangpeng Liao,
Vidhi Mody,
Neville McLean,
Ciara Metcalfe,
Michelle Nannini,
Daniel Otwine,
Yingqing Ran,
Nick Ray,
Fabien Roussel,
Amy Sambrone,
Deepak Sampath,
Maia Vinogradova,
John S. Wai,
Tao Wang,
Kuen Yeap,
Amy Young,
Jason R. Zbieg,
Birong Zhang,
Xiaoping Zheng,
Yu Zhong,
Xiaojing Wang
Publication year - 2020
Publication title -
acs medicinal chemistry letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 66
ISSN - 1948-5875
DOI - 10.1021/acsmedchemlett.0c00224
Subject(s) - fulvestrant , estrogen receptor , antagonist , estrogen receptor alpha , pharmacology , breast cancer , estrogen , chemistry , cancer research , cancer , medicine , receptor
Estrogen receptor alpha (ERα) is a well-validated drug target for ER-positive (ER+) breast cancer. Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms-as a full antagonist and selective estrogen receptor degrader (SERD)-but lacks oral bioavailability. Thus, we envisioned a "best-in-class" molecule with the same dual mechanisms as fulvestrant, but with significant oral exposure. Through lead optimization, we discovered a tool molecule 12 (GNE-149) with improved degradation and antiproliferative activity in both MCF7 and T47D cells. To illustrate the binding mode and key interactions of this scaffold with ERα, we obtained a cocrystal structure of 6 that showed ionic interaction of azetidine with Asp351 residue. Importantly, 12 showed favorable metabolic stability and good oral exposure. 12 exhibited antagonist effect in the uterus and demonstrated robust dose-dependent efficacy in xenograft models.